Search Result

Results for "

Epilepsy model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Calcium Channel (2) Cholinesterase (ChE) (1) Drug Derivative (1) Drug Metabolite (2) Fluorescent Dye (1) GABA Receptor (6) iGluR (3) Isotope-Labeled Compounds (2) mGluR (2) nAChR (1) Phosphatase (1) PKC (1) Potassium Channel (1) Sodium Channel (3) TRP Channel (1)
By Research Areas:	Inflammation/Immunology (1) Neurological Disease (23)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W012481

Nirvanol Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin	Drug Metabolite	Neurological Disease
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-109009

Padsevonil 1 Publications Verification UCB-0942	GABA Receptor	Neurological Disease
Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABA_AR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-107482

Picamilon Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid	GABA Receptor	Neurological Disease
Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-120546

Ulixacaltamide Z944; PRAX-944	Calcium Channel	Neurological Disease Inflammation/Immunology
Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .

HY-149422

NIR-FP	Fluorescent Dye	Neurological Disease
NIR-FP is a near-infrared fluorescent probe with high sensitivity and selectivity for superoxide anion O ^2-. O ^2- is the main precursor of ROS, and ferroptosis-mediated epilepsy models can be dynamically tracked by detecting O ^2-. Ferroptosis-mediated epilepsy models include: kainic acid (HY-N2309)-induced chronic epilepsy model, Pentylenetetrazole-induced acute epilepsy model, and pilocarpine (HY-B0726A)-induced epilepsy model .

HY-174899

AMPA-IN-2	iGluR	Neurological Disease
AMPA-IN-2 is an orally active AMPA inhibitor that can cross the blood-brain barrier. AMPA-IN-2 improves epileptic seizures by inhibiting the intrinsic excitability of neurons and inhibiting the excitability of glutamatergic transmission. AMPA-IN-2 exerts anti-epileptic effects in the pentylenetetrazol (PTZ) model and can be used as a promising candidates with high broad-spectrum anti-epileptic potential .

HY-P5918

Galanin-B2 NAX-5055	Biochemical Assay Reagents	Neurological Disease
Galanin-B2 (NAX-5055) has activity in the **epilepsy model. Galanin-B2 can penetrate the blood-brain-barrier** .

HY-162856

TRPV1-IN-2	TRP Channel	Neurological Disease
TRPV1-IN-2 ((R)-32) is a TRPV1 inhibitor. TRPV1-IN-2 has protective effects on ED epilepsy models .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-165514A

Nafimidone hydrochloride	Cholinesterase (ChE)	Neurological Disease
Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .

HY-107482A

Picamilon sodium Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate	GABA Receptor	Neurological Disease
Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-14948

Carisbamate RWJ-333369	Sodium Channel	Neurological Disease
Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-159819

Vormatrigine	Sodium Channel	Neurological Disease
Vormatrigine is an orally active sodium channel inhibitor with anti-epileptic activity. Vormatrigine has a specific inhibitory effect on overactive NaV channels in vitro and has a good inhibitory effect in the maximal electroconvulsive seizure (MES) model. Vormatrigine can be used to study human focal and generalized epilepsy .

HY-106469

Taltrimide MY-117	Drug Derivative	Neurological Disease
Taltrimide (MY-117), a lipophilic derivative of Taurine (HY-B0351), strongly inhibits the sodium-independent binding of Taurine to synaptic membranes of brain, the effects on the binding of GABA being less pronounced. Taltrimide exhibits definitive anticonvulsive effects in experimental epilepsy models .

HY-106670

Dulozafone F1933	Others	Neurological Disease
Dulozafone (F1933) shows anticonvulsant activity and can be used for epilepsy research .

HY-172887

Kv7.2/Kv7.3 activator-2	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC₅₀: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .

HY-109009A

(S)-Padsevonil (S)-UCB-0942	GABA Receptor	Neurological Disease
(S)-Padsevonil is the S-enantiomer of Padsevonil (HY-109009).Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABA_AR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-160955

Z218484536	Phosphatase	Neurological Disease
Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a K_d value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model[1].

HY-W012481S

Nirvanol-d5 Ethylphenylhydantoin-d₅; Phenylethyihydantoin-d₅; Desmethylmephenytoin-d₅	Isotope-Labeled Compounds Drug Metabolite	Neurological Disease
Nirvanol-d₅ (Ethylphenylhydantoin-d₅) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-W707539

Carisbamate-d2,-15N RWJ-333369-d_215N	Isotope-Labeled Compounds Sodium Channel	Neurological Disease
Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-155238

E2730	GABA Receptor	Neurological Disease
E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .

HY-155811

DQP-997-74	iGluR	Neurological Disease
DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC₅₀: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .

HY-B0340

Nefiracetam DM9384; DZL-221	nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .

Galanin-B2 NAX-5055	Biochemical Assay Reagents	Neurological Disease
Galanin-B2 (NAX-5055) has activity in the **epilepsy model. Galanin-B2 can penetrate the blood-brain-barrier** .

Cat. No.	Product Name	Chemical Structure

HY-W012481S

Nirvanol-d5
Nirvanol-d₅ (Ethylphenylhydantoin-d₅) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-W707539

Carisbamate-d2,-15N
Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

Carisbamate-d2,-15N

Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.